PDUFA dates November 2017: FDA calendar and catalysts.
0 PDUFA dates fell in November 2017. The FDA calendar also recorded 5 other catalysts that month, such as advisory committees and readouts, each quoted from the sponsor’s SEC filing or the FDA.
PDUFA dates in November 2017
No PDUFA dates are disclosed for this period as of November 16, 2026.
Download: CSV · JSON · iCal (next 30 days, CC BY 4.0) · Calendar API · All months
November 2017: other FDA decisions and filings
| Date | Drug | Company | Event | Indication | Status | Source |
|---|---|---|---|---|---|---|
| November 2, 2017 | Vyzulta (latanoprostene bunod) | BLCO | FDA approval | — | Approved | openFDA Drugs@FDA |
| November 3, 2017 | VELCADE® (bortezomib) | PFE | Complete Response Letter | — | CRL issued | FDA Complete Response Letters |
| November 8, 2017 | Prevymis (letermovir) | MRK | FDA approval | — | Approved | openFDA Drugs@FDA |
| November 14, 2017 | Fasenra (benralizumab) | AZN | FDA approval | — | Approved | openFDA Drugs@FDA |
| November 21, 2017 | Juluca (dolutegravir sodium; rilpivirine hydrochloride) | GSK | FDA approval | — | Approved | openFDA Drugs@FDA |
November 2017: dated readouts
No events in this view.
Questions
What PDUFA dates are in November 2017?
0 PDUFA dates fell in November 2017. The FDA calendar also recorded 5 other catalysts that month, such as advisory committees and readouts, each quoted from the sponsor’s SEC filing or the FDA.
Can these dates change?
Yes. The FDA can extend a review by three months after a major amendment, and it sometimes acts before the goal date. Each row links the filing the date came from.
Independent. Not affiliated with, endorsed by, or sponsored by the U.S. Securities and Exchange Commission. Data is reproduced from public SEC filings and datasets. Not investment advice.